Abstract has been shown to be a plasmacytoma growth factor in mice and is believed to play a key role in the development of human multiple myeloma. We investigated the IL-6 requirements for the growth of two human myeloma cell lines, U 266 and RPMI 8226. These cell lines secreted minute amounts of IL-6 (20 U/ml) and featured IL-6 mRNA. IL-6 receptors were detectable at the surface of malignant cells by immunofluorescence. Antibodies to IL-6 did not alter the proliferation of these myeloma cells. There was a dose-dependent decrease, however, in [3Hj-thymidine uptake in the presence of IL-6 antisense (and not sense) oligodeoxynucleotides; in the presence of 20 ,uM IL-6 antisense, an 80 and 95% inhibition of the proliferation of U 266 and RPMI 8226 cells was observed, respectively. These results provide strong evidence for an IL-6 autocrine proliferation of myeloma cells which may occur via internal interaction between IL-6 and the IL-6 receptor. (J. Clin. Invest. 1991. 88:696-699.)
Introduction
IL-6 has pleiotropic effects on a variety of cell types (reviewed in 1). It has been initially characterized as a murine plasmacytoma growth factor (2, 3) . This discovery led to important insights in the biology of human multiple myeloma (MM)' since it was demonstrated that this lymphokine might have a crucial role in the proliferation of malignant plasma cells (4) . However, the possibility of an IL-6 autocrine growth of myeloma cells is controversial since it has been shown that in most patients with MM the major source of IL-6 secretion is the bone marrow microenvironment, favoring a paracrine growth of plasma cells (5) . In view of the technical difficulties of obtaining purified plasma cell preparations from bone marrows, it is likely to be extremely difficult to distinguish between genuine autocrine factor production from a paracrine pathway. We therefore investigated the IL-6 requirements for growth of two well characterized human plasma cell lines, U 266 and RPMI 8226. Cells from both lines secreted minute amount of IL-6 and their proliferation was unaffected by neutralizing anti-IL-6 antibodies. Strikingly, myeloma cells proliferation was profoundly inhibited in the presence ofIL-6 antisense oligonucleotides providing strong evidence for an autocrine IL-6-dependent growth.
Methods
Myeloma cell lines. U 266 (6) and RPMI 8226 (7) myeloma cell lines secreting IgEX and X molecules, respectively, were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum inactivated for 45 min at 650C, 2 mM L-glutamine, and antibiotics.
IL-6 sense and antisense oligonucleotides. A 1 5-base antisense oligodeoxynucleotide (TCCTGGGGGTACTGG) specific for a sequence in the second exon of the IL-6 gene (8, 9) was prepared (Genset, Paris, France). A control sense oligonucleotide was used in each experiment. Various concentrations (2, 10, and 20 uM) of both oligonucleotides were tested. Oligonucleotides were purified by HPLC and electrophoresis on polyacrylamide gels.
Culture of U 266 and RPMI 8226 myeloma cells in the presence of IL-6 antisense andsense oligonucleotides andanti-IL-6 antibodies. Myeloma cell lines were cultured for 6 h in serum-free medium. After three washes, cells were resuspended at 1O cells in 0.1 ml ofculture medium containing 2.5% of fetal bovine serum and plated in 96-well plates for 48 h. Various concentrations of IL-6 antisense and control IL-6 sense oligonucleotides were added at the onset ofthe culture period. In some experiments purified goat anti-IL-6 neutralizing antibodies (generous gift from T. Hirano and T. Kishimoto, Osaka, Japan) at a 1:10,000 final dilution, or rabbit anti-IL-6 antibodies (10-30 zg/ml; Genzyme Corp., Boston, MA) were added at the beginning of the culture. Purified goat or rabbit IgG were used as controls. In another set of experiments, various concentrations ofrecombinant IL-6 (rIL-6) (Boehringer Mannheim GmbH, Mannheim, FRG) (10-100 pg/ml) were included in cell cultures containing IL-6 antisense and sense nucleotides. (12) . RNA was blotted to nitrocellulose filters (Hybond C-E; Amersham). Prehybridization, hybridization, and washing were carried out as previously described (13) . Films (X-OMAT AR; Kodak) were exposed at -80'C for
Probes. IL-6 and IL-6 receptor (IL-6R) probes (a generous gift from Dr. T. Kishimoto), were 32P-labeled by the hexanucleotide random primer method (14) , using a Boehringer kit and a-22P-labeled dCTP (Dupont de Nemours, France) at 3,000 Ci/mmol.
Results
We evaluated the IL-6 requirements for growth of two human myeloma cell lines, U 266 and RPMI 8226 secreting IgE X and X molecules, respectively. A twofold increase in [3H]-TdR uptake was noted in the presence of 100 pg/ml of rIL-6 (data not shown, and see Fig. 3 ). The IL-6 content of supernatants from both cell lines cultured for 48 h at a concentration of 106 cells/ ml was 20 U/ml. A normal sized mRNA for IL-6 was detected in both lines (Fig. 1) Fig. 2, A bioactivity (< 5 U/ml). Both oligonucleotides did not alter the T-derived MOLT4 cell line proliferation (Fig. 2 A) . The IL-6 antisense inhibition of myeloma cell proliferation was partly restored in the presence of 100 pg/ml of IL-6 (Fig. 3) . '°0 '°°of 100 pg/ml of rIL-6 in all culture IL-6 concentration (pg/mi) conditions.
short-term cultures, cannot by itself allow the establishment of permanent cell lines (15 Several lines ofevidence suggest that IL-6 may be an example of such a transforming growth factor. For instance, transfection of the human IL-6 gene in murine plasmacytoma or hybridoma led to increased tumorigenicity (21, 22) . On the other hand, IL-6 gene transgenic mice exhibit a striking plasmacytosis but no transplantable plasma cell tumor could be obtained (23) . It is conceivable that acquired, and still undefined, additional genetic changes might render some B cells more susceptible to autonomous growth depending upon intracellular growth factor stimulation. Of note, the IL-6 and IL-6R genes from both lines which were studied exhibited no detectable structural alterations as assessed by Southern analysis with several restriction enzymes (data not shown).
These findings are particularly relevant to the biology of human MM. The establishment of myeloma cell lines is quite difficult. Recent studies taking advantage ofthe role of various growth factors including IL-6 but also granulocyte macrophage colony-stimulating factor or monocyte-derived conditioned medium allowed the production of factor-dependent cell lines that eventually grow autonomously (15, 24) . Most of these lines arise from plasma cells obtained in patients with aggressive, extra osseous myelomas. An appealing hypothesis would be that the IL-6 autocrine myeloma cell lines that were used in our study are representative of the so-called myeloma stem cells (25) . These cells give rise in vitro to malignant colonies (25) and are believed to replenish the large pool ofnondividing plasma cells. The latter may be triggered to proliferate by IL-6 external stimulation only. This model would be compatible with most published data on the role of IL-6 in multiple myeloma. Interestingly, it has been shown that the mature, nonproliferating, progeny of leukemic myeloid blast cells produce the growth factor that stimulates the blast cells (26) . Finally, it should be emphasized that therapeutic trials with monoclonal antibodies designed to neutralize IL-6 or to compete with this lymphokine for IL-6R occupancy will likely fail to eradicate IL-6 autocrine cells such as those we have characterized here.
